Initiate a Phase 3 trial of imsidolimab in generalized pustular psoriasis
Delivered after the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 25 Feb 2021
- Due
- 31 Jul 2021
- Delivered
- by 4 Oct 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“We anticipate initiation of a Phase 3 trial for imsidolimab in GPP during mid-2021 following completion of protocol alignment, and review of 16-week data”
What we found
Evidence strength A What the grades mean
The August 2021 10-Q still anticipated initiation in Q3 2021, after the July deadline. By the October 2021 8-K the GEMINI-1 Phase 3 trial was reported as initiated.
-
A Anaptysbio, Inc. 8-K filed 2021-08-09
“Imsidolimab GPP GEMINI-1 Phase 3 trial anticipated to initiate in Q3 2021 following recent FDA end-of-Phase 2 Meeting” ✓ confirmed on the page
-
A Anaptysbio, Inc. 10-Q filed 2021-08-09
“We anticipate initiating our Phase 3 registrational trials for imsidolimab for GPP, called GEMINI-1 and GEMINI-2, in the third quarter of 2021.” ✓ confirmed on the page
-
A Anaptysbio, Inc. 8-K filed 2021-10-04
“Phase 3 GEMINI-1 clinical trial has been initiated subsequent to FDA end-of-Phase 2 meeting and FDA orphan drug designation for the treatment of GPP” ✓ confirmed on the page
-
A Anaptysbio, Inc. 10-Q filed 2021-11-04
“We have initiated our first Phase 3 trial for imsidolimab for GPP, called GEMINI-1, during the third quarter of 2021.” ✓ confirmed on the page
Checked 27 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Phase 3 trial of imsidolimab in GPP
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
- Conditional
- Yes: following completion of protocol alignment and review of 16-week data with the FDA
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Anaptysbio, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-ANAB-024535 · Corrections policy